Purinergic P2Y Receptor Antagonists
"Purinergic P2Y Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that bind to and block the stimulation of PURINERGIC P2Y RECEPTORS. Included under this heading are antagonists for specific P2Y receptor subtypes.
| Descriptor ID |
D058921
|
| MeSH Number(s) |
D27.505.519.625.725.400.200.200 D27.505.696.577.725.400.200.200
|
| Concept/Terms |
Purinergic P2Y12 Receptor Antagonists- Purinergic P2Y12 Receptor Antagonists
- P2Y12 Receptor Antagonists
- Antagonists, P2Y12 Receptor
- Receptor Antagonists, P2Y12
- P2Y12 Purinoceptor Antagonists
- Antagonists, P2Y12 Purinoceptor
- Purinoceptor Antagonists, P2Y12
|
Below are MeSH descriptors whose meaning is more general than "Purinergic P2Y Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Purinergic P2Y Receptor Antagonists".
This graph shows the total number of publications written about "Purinergic P2Y Receptor Antagonists" by people in this website by year, and whether "Purinergic P2Y Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 1 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 2 | 2 |
| 2018 | 3 | 1 | 4 |
| 2019 | 0 | 2 | 2 |
| 2020 | 1 | 2 | 3 |
| 2021 | 1 | 0 | 1 |
| 2022 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Purinergic P2Y Receptor Antagonists" by people in Profiles.
-
Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y12 Inhibitor Prescribing After Percutaneous Coronary Intervention. Clin Pharmacol Ther. 2023 03; 113(3):615-623.
-
A Comprehensive Review of the Pleiotropic Effects of Ticagrelor. Cardiovasc Drugs Ther. 2024 08; 38(4):775-797.
-
The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Cardiovasc Drugs Ther. 2024 06; 38(3):605-619.
-
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Cardiovasc Revasc Med. 2022 08; 41:115-121.
-
Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review. JAMA. 2021 Apr 20; 325(15):1545-1555.
-
Rotavirus induces intercellular calcium waves through ADP signaling. Science. 2020 11 20; 370(6519).
-
Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay. Cardiovasc Drugs Ther. 2020 08; 34(4):443-461.
-
Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program. Circ Cardiovasc Qual Outcomes. 2019 11; 12(11):e005455.
-
Ticagrelor induces paraoxonase-1 (PON1) and better protects hypercholesterolemic mice against atherosclerosis compared to clopidogrel. PLoS One. 2019; 14(6):e0218934.
-
Size matters in STEMI: time for translation of ticagrelor? Cardiovasc Res. 2018 12 01; 114(14):1817-1818.